vaccine from analysis of epitopes 3 in the bank of viral sequences in the Los Alamos database 4 . This discrepancy, in part, reflected mutations outside of the currently recognized epitopes compromising the ability of these epitopes to undergo antigen processing and presentation. Indeed, at least one epitope that was perfectly conserved between the first and second viruses failed to undergo antigen presentation for the superinfecting virus. An encouraging aspect of AC-06's response to his second virus was the mounting of three ELISPOT responses that were unique to the new virus with at least two of these responses being the particularly effective, high avidity responses that require only low concentrations (<5 nM) of peptide for maximal functional activity 5 . However, these 15 targets, 12 of which were conserved and thus poorly tolerant of immune escape and at least two of which were high avidity, did not allow him to successfully control the superinfection. What went wrong? Will our T cell vaccines offer hope for preventive immunizations against the diversity of human infections?
The rationale, for those of us who are developing T cell vaccines, to soldier on comes from a consideration of the actual battle between virus and host in patient AC-06 compared to those in macaques in our vaccine trial, infected humans who are long term nonprogressors and infected humans who are progressors ( Table 1) . The first striking difference between our vaccinated and challenged macaques and AC-06 is an at least ten-times more stringent viral control in the vaccinated macaques than in AC-06, whose fluctuating titers of virus placed him between HIV-1-infected long-term nonprogressors and progressors 6 . A second difference is the rock-stable maintenance of CD4 + T cells in our macaques compared to the fluctuating numbers in AC-06. Also, in contrast to AC-06, in our vaccinated and challenged macaques, specific CD8 + T cells are both low frequency and of limited breadth because of the very low titers of persisting virus. Most epitopes that were observed at the peak vaccine or post-challenge response are now below the level of detection and presumed to be in memory. In contrast, AC-06's T cell response was similar in both height and breadth to what is seen for progressors who have not reached frank AIDS 7 . AC-06's T cells were able to produce IFN-γ after peptide stimulation and did have lytic activity, but were they able to undergo the proliferative responses that distinguish IFN-γ-producing CD8 + T cells in progressors and long-term nonprogressors 7 ? Such proliferative responses are key to effective viral control in mouse models 8 and likely to be key to effective viral control in human models. An infection can escape a T cell vaccine by mutating its epitopes 9 . However, an infection can also exhaust its T cell response, especially in the presence of continuing antigenic stimulation and suboptimal T cell help 10, 11 . In short, AC-06 appears to have been slowly losing control, not so much because of his virus mutating and undergoing T cell escape, but because of his anti-HIV T cells slipping into exhaustion during their unrelenting encounters with virusexpressing cells. Whether the slowly declining titers of residual virus in our macaques will also erode the T cell response or lead to escape will only be known with time 12 . Meanwhile, we can only speculate that if AC-06 had enjoyed a fully functional CD8 + T cell response, capable of proliferation as well as IFN-γ production, he would have exhibited better control of the superinfecting virus.
Despite the failure of T cell-mediated antiviral control in AC-06, it is important to advance 'T cell vaccines' into efficacy trials to test whether vaccinating before infection can provide long-term control of a challenge. Both the databases and the findings in AC-06 indicate that the epitopes in a T cell vaccine, at best, will match only about 50% of the potential CD8 epitopes in a challenge infection. To prevent CD8 exhaustion and minimize the generation of mutations that support escape, this level of match will need to provide both rapid and stringent control of viremia. But given that both rapid and stringent control can be achieved, both the battles of exhaustion and escape should be tipped towards the T cell and the host they are protecting, and away from the virus and the pandemic it is causing.
Checks and balances on developing B cells TOMOHIRO KUROSAKI Signals through the pre-BCR play key roles in B cell development. New data reveal how two downstream components, SLP-65 and the tyrosine kinase Abl, regulate pre-BCR surface expression and immunoglobulin light chain expression. 
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programmed cell death. Thus, the pre-BCR acts as a biological sensor that informs B cells that they have succeeded in making a functional Ig heavy chain, thereby permitting them to further proceed in B cell ontogeny and initiate light chain gene rearrangement (Fig. 1a) .
Although the importance of the pre-BCR by itself has been well documented with the use of mice deficient in each pre-BCR component, little is known about what and how signaling molecules downstream of the pre-BCR control proliferation of pre-B cells. In this issue of Nature Immunology, Flemming et al. 1 show that pre-B cells lacking SLP-65 (also known as BLNK or BASH), a B cell-specific adaptor molecule, have an enhanced proliferative capability, somewhat unexpectedly, and that this anomaly could be due to a defect in pre-BCR down-regulation. Their data-given the importance of a cessation of proliferation in large pre-B cells, transition from large pre-B to socalled small pre-B cells (Fig. 1a) , for subsequent differentiation-provide new insights into the mechanism by which the pre-BCR regulates differentiation. This differentiation process was also the focus of Muljo and Schlissel 2 , who used a model of Abl kinase inhibition for the transition from pre-B to immature B stage, to understand the unresolved mechanism of how Igκ light chain transcription and subsequent light chain gene rearrangement is activated in small pre-B cells (Fig. 1a) . They identify the genes encoding transcription factors Spi-B and IRF-4 as targets of Abl inhibition, being capable of inducing Igκ transcription in Abl-transformed pre-B cells, and show specific expression of Spi-B and IRF-4 in small pre-B cells harvested from mice, suggesting these proteins play key roles in normal B cell ontogeny as well.
SLP-65 was first isolated as one of the rapidly tyrosine-phosphorylated proteins upon BCR cross-linking and turned out to be a good substrate for Syk, a nonreceptor tyrosine kinase. The biochemical nature of pre-BCR signal has not been well analyzed. But, extrapolated from studies of BCR signaling, it is thought that, after the appearance of the pre-BCR on the cell surface, tyrosine residues in Igα and Igβ are phosphorylated (presumably by Src family tyrosine kinases such as Lyn), thereby recruiting Syk and SLP-65 to the pre-BCR 3 (Fig. 1b) . In SLP-65 -/-mice, the number of small pre-B cells is dramatically decreased, but the number of large pre-B cells is reciprocally increased [4] [5] [6] . Based on these previous observations, Flemming et al., by using an in vitro culture system in the presence of IL-7, have asked whether this is caused by a block in differentiation or by an enhanced proliferation of large Another potential mechanism is that SLP-65 targets the pre-BCR for internalization and degradation apparatus. In the case of the T cell receptor (TCR), TCR down-modulation is known to result from intracellular retention and degradation of the receptor by lysosomes and proteasomes 11 . In this regard, as Cbl is known to interact directly with SLP-65 12 and to act as an E3 ubiqitin-protein ligase 13 , the SLP-65-Cbl complex may target proteosomal pre-BCR degradation.
A more severe pre-B cell developmental block is seen in Syk -/-mice; for instance, the number of large cycling pre-B cells is decreased in Syk -/-mice 14, 15 , in contrast to their increase in SLP-65 -/-mice [4] [5] [6] . Considering the notion that Syk acts upstream of SLP-65 in pre-BCR signaling (Fig. 1b) , analogous to BCR signals 3 , Syk may play a crucial role in initiating pre-B cell proliferation. SLP-65 could function to limit or halt this proliferation. If so, a question arises about which molecules participate in Syk-mediated proliferation. Because an inhibitor of the Ras-extracellular signal-regulated kinase (Ras-Erk) pathway prevented SLP-65 -/-pre-B cell sur- Using DNA microarray analyses with or without STI571, Muljo and Schlissel identified many genes whose expression was increased upon Abl inhibition. In the context of gene products that can induce κ light chain transcription, they considered that Spi-B and IRF-4, whose expression was eight-and tenfold higher upon Abl inhibition, respectively, to be good candidates for the following reasons. First, Spi-B and IRF-4 are transcription factors of the Ets and IRF families, respectively, and second, a canonical Ets-IRF composite binding site (called EICE) exists in the Igκ3′ enhancer region (Eκ3′). The κ light chain locus contains two developmentally regulated transcription enhancers, the intronic enhancer (Eκi) and the 3′κ enhancer (Eκ3′). Eκ3′ is thought to be more important for inducing germline κ transcription at small pre-B stage 16 . In addition to the above structural consideration, Muljo and Schlissel provided functional data: gemline κ transcriptional was in fact induced by enforced expression of both Spi-B and IRF-4 in AMuLV-transformed B cells 2 . However, it is unclear at the present time whether one of these transcription factors is sufficient or not.
Together, these findings demonstrate that activation of Spi-B and IRF-4, upon Abl inhibition, is capable of inducing κ locus transcription and possibly recombination accessibility (Fig. 1b) . What about primary B cells? Consistent during B cell ontogeny, when a κ germline transcript emerges, expression of Spi-B and IRF-4 was also high at the small pre-B cell stage.
Spi-B, as well as a closely related transcription factor, PU.1, commonly partners with IRF-4 to regulate the transcription of target genes by binding to EICE. In addition to the EICE, the Eκ3′ has an adjacent Pax-5 binding site. A reciprocal binding pattern between these two binding sites was observed: the Pax-5 binding site, but not the EICE site, was occupied in pro-B cells, whereas Pax-5-association could no longer be detected, but the EICE was occupied in small pre-B cells 16 . Based on these findings, Muljo and Schlissel propose that once Spi-B and IRF-4 are expressed at the small pre-B stage, this binding to the EICE removes Pax-5 from Eκ3′, allowing for transcriptional activation of the Igκ.
So, Spi-B and IRF-4 appear to be turned on upon Abl inhibition. But the question that then arises is whether Abl inhibition occurs during normal B cell development. Although direct evidence is not currently available, given that Abl is activated by DNA damage, Muljo and Schlissel speculate that once V(D)J rearrangement has ceased at the IgH locus, thereby extinguishing any DNA damage signals, Abl is then inactivated. In this regard, Abl might function as a molecular safeguard, like p53, to survey the status of ongoing gene rearrangement.
Spi-B and IRF-4 could be induced by other means, such as pre-BCR signaling and/or Pax-5 expression. Studying these connections will help to establish how these transcription factors are regulated by extracellular and intrinsic cues. Particularly, the former connection is likely to operate, given the recent evidence that κ transcription is decreased in SLP-65 -/-mice 17 . So, does SLP-65 mediate induction of Spi-B-IRF-4 or utilize a different way to induce Igκ transcription? Alternatively, does the decreased Igκ transcription in SLP-65 -/-mice reflect the decreased number of small pre-B cells, rather than a more direct involvement of SLP-65 in transcriptional events? No matter how the story turns out, it is clear that the growth and differentiation of a pre-B cell is an active and highly regulated process. Understanding the networks that regulate these well organized processes is still an important challenge.
